VRNA
Verona Pharma plcCompany Information
- Company Name
- Verona Pharma plc
- CIK
- CIK0001657312
- Category
- Large accelerated filer
- Ticker: Exchange
- VRNA: None
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- VRNA
SEC filing data through
Insider Sentiment
- Last purchase
- 2024-11-18
- Last sale
- 2025-08-01
- Shares purchased (TTM)
- 137,240
- Shares sold (TTM)
- 6,655,080
Institutional Sentiment
- As of
- 2025-09-30
- Institutional shares owned
- 68,480,850
- Shares outstanding
- 685,155,000
- Ownership
- 9.99%
Earnings Market Reaction
- Filing date
- —
- Price on filing date
- —
- 1-month reaction
- —
- 3-month reaction
- —
Balance Sheet
Values in millions ($)| Line item | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 438 | 401 | 400 | 336 | 405 | 255 | 272 | 257 | 271 | 291 | 228 | 232 | ||||||
| Accounts Receivable Net Current | 83 | 62 | 31 | 7 | - | - | 0 | - | - | - | - | - | ||||||
| Prepaid Expense Current | 11 | 11 | 8 | 8 | 5 | 4 | 4 | 3 | 1 | 2 | 2 | 3 | ||||||
Assets Current | ||||||||||||||||||
| Assets Current | 549 | 501 | 454 | 364 | 416 | 272 | 290 | 277 | 288 | 307 | 243 | 258 | ||||||
| Inventory Net | 9 | 7 | 6 | 4 | - | - | 0 | - | - | - | - | - | ||||||
| Other Assets Current | 4 | 13 | 3 | 3 | 3 | 2 | 3 | 6 | 6 | 2 | 3 | 3 | ||||||
| Property Plant And Equipment Net | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Inventory Noncurrent | 6 | 7 | 2 | - | - | - | 0 | - | - | - | - | - | ||||||
Assets Noncurrent | ||||||||||||||||||
| Assets Noncurrent | 24 | 25 | 21 | 18 | 18 | 18 | 18 | 16 | 16 | 16 | 16 | 16 | ||||||
| Goodwill | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Contract With Customer Asset Net Noncurrent | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 15 | ||||||
| Operating Lease Right Of Use Asset | 2 | 2 | 2 | 2 | 2 | 3 | 3 | 0 | 1 | 1 | 1 | 1 | ||||||
| Assets | 573 | 526 | 474 | 382 | 434 | 290 | 308 | 292 | 304 | 323 | 259 | 275 | ||||||
Liabilities And Stockholders Equity | ||||||||||||||||||
| Accounts Payable Current | 3 | 9 | 11 | 7 | 4 | 5 | 3 | 1 | 2 | 7 | 3 | 8 | ||||||
| Accrued Liabilities Current | 43 | 32 | 17 | 18 | 20 | 8 | 4 | 7 | 7 | 18 | 14 | 23 | ||||||
| Accrued Royalties Current And Noncurrent | 3 | 4 | 1 | - | - | - | 0 | - | - | - | - | - | ||||||
Liabilities Current | ||||||||||||||||||
| Contract With Customer Liability Current | - | 0 | 1 | 0 | 21 | - | 0 | - | - | - | - | - | ||||||
| Liabilities Current | 51 | 57 | 43 | 28 | 48 | 15 | 9 | 9 | 11 | 27 | 19 | 32 | ||||||
| Operating Lease Liability Current | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | ||||||
| Taxes Payable Current | 0 | 9 | 9 | 1 | 1 | - | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Other Liabilities Current | 0 | 1 | 3 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | ||||||
| Long Term Debt Noncurrent | 242 | 242 | 120 | 120 | 120 | 49 | 48 | 20 | 20 | 20 | 10 | 5 | ||||||
Liabilities Noncurrent | ||||||||||||||||||
| Contract With Customer Liability Noncurrent | - | - | 105 | - | - | - | 0 | - | - | - | - | - | ||||||
| Liabilities Noncurrent | 243 | 243 | 227 | 223 | 218 | 50 | 50 | 20 | 20 | 20 | 10 | 5 | ||||||
| Operating Lease Liability Noncurrent | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 0 | 0 | 0 | 0 | 0 | ||||||
| Liabilities | 295 | 299 | 270 | 251 | 266 | 65 | 59 | 29 | 31 | 46 | 29 | 37 | ||||||
| Common Stock Value | 45 | 45 | 45 | 43 | 43 | 43 | 43 | 42 | 42 | 42 | 41 | 39 | ||||||
| Additional Paid In Capital | 806 | 766 | 728 | 622 | 617 | 602 | 601 | 601 | 596 | 591 | 529 | 526 | ||||||
Stockholders Equity | ||||||||||||||||||
| Stockholders Equity | 278 | 227 | 205 | 130 | 168 | 225 | 249 | 264 | 273 | 277 | 230 | 237 | ||||||
| Treasury Stock Value | -1 | -1 | -2 | -1 | -1 | -1 | -2 | -1 | -1 | -1 | -2 | -0 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -5 | -5 | -5 | -5 | -5 | -5 | -5 | -5 | -5 | -5 | -5 | -5 | ||||||
| Retained Earnings Accumulated Deficit | -567 | -579 | -562 | -528 | -485 | -414 | -388 | -374 | -359 | -350 | -333 | -322 | ||||||
| Liabilities And Stockholders Equity | 573 | 526 | 474 | 382 | 434 | 290 | 308 | 292 | 304 | 323 | 259 | 275 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | ||||||
| Common Stock Shares Issued | 703 | 703 | 703 | 668 | 668 | 668 | 668 | 652 | 652 | 652 | 631 | 608 | ||||||
| Shares Outstanding | 688 | 681 | - | 655 | 649 | 647 | 644 | 640 | 636 | 632 | 606 | 602 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialVerona Pharma plc (VRNA) — SEC Financial Statements & Analysis
Verona Pharma plc (VRNA) is a pharmaceutical preparations company, incorporated in X0. Verona Pharma plc trades on None as: VRNA. Verona Pharma plc (VRNA)'s most recent SEC filing is a Form 10-Q for the period ended 2025-06-30, filed with the SEC on 2025-08-06. Based on that filing, On profitability, Verona Pharma plc posts an operating margin of -25.27%, a net margin of -36.62%, a Return on Equity (ROE) of -36.36%, a Return on Assets (ROA) of -16.12%, and a Return on Invested Capital (ROIC) of -294.43%. Per share, it reports EPS of $-0.12, diluted EPS of $-0.11, free cash flow per share of $-0.11, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 1127.95% year-over-year, net income growth of -35.28% year-over-year, and EPS growth of -38.77% year-over-year. On the balance sheet, it maintains a current ratio of 10.71x, a quick ratio of 10.32x, working capital of $497.61M, a debt-to-equity ratio of 1.06x, a debt ratio of 0.51, an interest coverage ratio of -2.08x, free cash flow of $-73.65M (TTM), and net debt of $-195.58M. Figures sourced from SEC EDGAR.
- EPS TTM
- $-0.12
- ROE TTM
- -36.36%
- ROA TTM
- -16.12%
- Debt To Equity
- 1.06x
- Free Cash Flow TTM
- $-73.65M
- Net Revenue TTM Growth 1Y
- 1127.95%
Data as of 2025-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Verona Pharma plc in?
Verona Pharma plc (VRNA) operates in the Pharmaceutical Preparations industry.
What exchange does VRNA trade on?
Verona Pharma plc (VRNA) trades on the None.
Where is Verona Pharma plc incorporated?
Verona Pharma plc is incorporated in United Kingdom.
When was Verona Pharma plc (VRNA)'s most recent SEC filing?
Verona Pharma plc (VRNA)'s most recent SEC filing is a Form 10-Q for the period ended 2025-06-30, filed with the SEC on 2025-08-06.
What is VRNA's EPS (earnings per share)?
Verona Pharma plc (VRNA)'s trailing twelve month EPS is $-0.12 as of 2025-06-30.
What is VRNA's ROE (return on equity)?
Verona Pharma plc (VRNA)'s trailing twelve month Return on Equity (ROE) is -36.36% as of 2025-06-30.
What is VRNA's ROA (return on assets)?
Verona Pharma plc (VRNA)'s trailing twelve month Return on Assets (ROA) is -16.12% as of 2025-06-30.
What is VRNA's ROIC (return on invested capital)?
Verona Pharma plc (VRNA)'s trailing twelve month Return on Invested Capital (ROIC) is -294.43% as of 2025-03-31.